Articles producció científica> Medicina i Cirurgia

Pharmacological considerations for the treatment of COVID-19 in people living with HIV (PLWH)

  • Datos identificativos

    Identificador: imarina:9172959
    Autores:
    Gutierrez, Maria Del MarMur, IsabelMateo, Maria GraciaVidal, FrancescDomingo, Pere
    Resumen:
    Introduction When coronavirus infectious disease-2019 (COVID-19) blew up, ill-fated auguries on the collision between COVID-19 and the human immunodeficiency virus (HIV) epidemics loomed. Areas covered Data from observational studies suggest similar incidence attacks of SARS-CoV-2 infection in people living with HIV (PLWH) and HIV-uninfected populations. The mortality rate of COVID-19 is similar in both populations too. The authors discuss the role of combination antiretroviral therapy (cART) in preventing infection or reducing COVID-19 severity. They also discuss the pharmacological interventions for COVID-19 in PLWH. Expert opinion Management of COVID-19 in PLWH is no different from the general population. It should be based on careful supportive care, emphasizing lung-protective ventilation, and wise pharmacological interventions. The antiviral drug remdesivir and dexamethasone are the only pharmacological interventions with clinical benefit for COVID-19, whereas anticoagulation may prevent thrombotic complications. The experience with using these drugs in PLWH is limited, which prevents from rendering well-founded conclusions. Until more data on COVID-19 in PLWH become available, the best weapons within our reach are sound supportive care and sensible use of RDV and dexamethasone, bearing in mind the potential for drug-drug interactions of most corticosteroids and antiretroviral drugs.
  • Otros:

    Autor según el artículo: Gutierrez, Maria Del Mar; Mur, Isabel; Mateo, Maria Gracia; Vidal, Francesc; Domingo, Pere;
    Departamento: Medicina i Cirurgia
    Autor/es de la URV: Vidal Marsal, Francisco
    Palabras clave: Tdf Sars-cov-2 Risk factor Remdesivir Randomized controlled trial (topic) R Prevalence Nonhuman Mortality rate Lpv/r Lpv Janus kinase inhibitor Interferon Infliximab Immunomodulating agent Il-6 antagonists Hydroxychloroquine Humans Human immunodeficiency virus infection Human immunodeficiency virus infected patient Human Hiv infections Ftc Drv Drug mechanism Disease severity Dexamethasone Cytokine receptor antagonist Covid-19 Corticosteroid Coronavirus disease 2019 Complication Clinical outcome Chloroquine Cart Bevacizumab Azithromycin Article Antivirus agent Antiviral therapy Antiviral agents Antiretrovirus agent Antiretroviral therapy Anticoagulant therapy Anti-sars-cov-2 agent Anti-retroviral agents Anakinra Adalimumab
    Resumen: Introduction When coronavirus infectious disease-2019 (COVID-19) blew up, ill-fated auguries on the collision between COVID-19 and the human immunodeficiency virus (HIV) epidemics loomed. Areas covered Data from observational studies suggest similar incidence attacks of SARS-CoV-2 infection in people living with HIV (PLWH) and HIV-uninfected populations. The mortality rate of COVID-19 is similar in both populations too. The authors discuss the role of combination antiretroviral therapy (cART) in preventing infection or reducing COVID-19 severity. They also discuss the pharmacological interventions for COVID-19 in PLWH. Expert opinion Management of COVID-19 in PLWH is no different from the general population. It should be based on careful supportive care, emphasizing lung-protective ventilation, and wise pharmacological interventions. The antiviral drug remdesivir and dexamethasone are the only pharmacological interventions with clinical benefit for COVID-19, whereas anticoagulation may prevent thrombotic complications. The experience with using these drugs in PLWH is limited, which prevents from rendering well-founded conclusions. Until more data on COVID-19 in PLWH become available, the best weapons within our reach are sound supportive care and sensible use of RDV and dexamethasone, bearing in mind the potential for drug-drug interactions of most corticosteroids and antiretroviral drugs.
    Áreas temáticas: Saúde coletiva Pharmacology (medical) Pharmacology & pharmacy Pharmacology Medicine (miscellaneous) Medicina iii Medicina ii Medicina i General medicine Farmacia Ciências biológicas ii
    Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/
    Direcció de correo del autor: francesc.vidal@urv.cat
    Identificador del autor: 0000-0002-6692-6186
    Fecha de alta del registro: 2024-07-27
    Versión del articulo depositado: info:eu-repo/semantics/publishedVersion
    Enlace a la fuente original: https://www.tandfonline.com/doi/full/10.1080/14656566.2021.1887140
    URL Documento de licencia: https://repositori.urv.cat/ca/proteccio-de-dades/
    Referencia al articulo segun fuente origial: Expert Opinion On Pharmacotherapy. 22 (9): 1127-1141
    Referencia de l'ítem segons les normes APA: Gutierrez, Maria Del Mar; Mur, Isabel; Mateo, Maria Gracia; Vidal, Francesc; Domingo, Pere; (2021). Pharmacological considerations for the treatment of COVID-19 in people living with HIV (PLWH). Expert Opinion On Pharmacotherapy, 22(9), 1127-1141. DOI: 10.1080/14656566.2021.1887140
    DOI del artículo: 10.1080/14656566.2021.1887140
    Entidad: Universitat Rovira i Virgili
    Año de publicación de la revista: 2021
    Tipo de publicación: Journal Publications
  • Palabras clave:

    Medicine (Miscellaneous),Pharmacology,Pharmacology & Pharmacy,Pharmacology (Medical)
    Tdf
    Sars-cov-2
    Risk factor
    Remdesivir
    Randomized controlled trial (topic)
    R
    Prevalence
    Nonhuman
    Mortality rate
    Lpv/r
    Lpv
    Janus kinase inhibitor
    Interferon
    Infliximab
    Immunomodulating agent
    Il-6 antagonists
    Hydroxychloroquine
    Humans
    Human immunodeficiency virus infection
    Human immunodeficiency virus infected patient
    Human
    Hiv infections
    Ftc
    Drv
    Drug mechanism
    Disease severity
    Dexamethasone
    Cytokine receptor antagonist
    Covid-19
    Corticosteroid
    Coronavirus disease 2019
    Complication
    Clinical outcome
    Chloroquine
    Cart
    Bevacizumab
    Azithromycin
    Article
    Antivirus agent
    Antiviral therapy
    Antiviral agents
    Antiretrovirus agent
    Antiretroviral therapy
    Anticoagulant therapy
    Anti-sars-cov-2 agent
    Anti-retroviral agents
    Anakinra
    Adalimumab
    Saúde coletiva
    Pharmacology (medical)
    Pharmacology & pharmacy
    Pharmacology
    Medicine (miscellaneous)
    Medicina iii
    Medicina ii
    Medicina i
    General medicine
    Farmacia
    Ciências biológicas ii
  • Documentos:

  • Cerca a google

    Search to google scholar